Although the combination of ERK1/2 and EGFR blockade in breast cancer has been demonstrated before using MEK1/2-inhibitors [66,67], combination in the context of CAM-DR or COL1 dependency have not been described so far. Here, MAP2K1 is linked to breast cancer.